Quest for success: Innovative strategies to accelerate bispecific antibody production

Watch this on-demand webinar to learn strategies to drive workflow efficiencies and characterize superior antibody drugs

2 May 2023
Jemima Arnold
Editorial Assistant
Clare Mills, professor of molecular allergology at the University of Manchester, and Dr Jayne Kirk, a principle product manager at Waters

In this free on-demand SelectScience® webinar, join Dr. Christina Tsai, Head of cell line development at IGM Biosciences, and Jen Carlstrom, Senior Scientist/Project Manager at PerkinElmer as they introduce a new, high-throughput bioanalytical platform to expedite cell line development and discuss how to overcome challenges associated with bispecific antibodies (bsAbs).

Heralded as the fourth wave of biopharmaceutical innovation, bsAbs are designed and manufactured to target multiple antigens with a single therapeutic. Bioprocessing workflows for bsAb production include critical steps such as antibody screening, characterization, multi-specific drug targetability testing and cell line development. Cell line processing has been enhanced by using automated technologies and high-throughput analysis of single-cell cloning, cell expansion, and cell growth analysis. Despite these advancements, challenges remain with bioanalytical assay productivity to evaluate biotherapeutic quality.

Key learning objectives

  • Learn about a new, high-throughput bioanalytical platform to expedite cell line development
  • Discover how to mitigate screening and characterization challenges of a multi-specific therapeutic
  • Use insights and knowledge gained from this webinar to inform process development and drug discovery workflows

Read on for highlights from the live Q&A session, or watch the webinar on demand, at a time that suits you.

Can these assay protocols work for the concentration of excipients in formulations?

JC: This is dependent on whether or not the excipients can be bound to the sodium dodecyl sulfate (SDS) to be able to be detected in the LabChip. The lowest size is around five kilotons, meaning if it’s a protein stabilizer in your formulation, you would be able to detect it.

Does the AlphaPlex™ assay work on other bispecific antibody formats or species, besides the one you showed today?

JC: There’s a published paper in The Journal of Immunological Methods by Christian, E.A. et al, where they used a DuetMab bispecific antibody, and similar to what we showed with the AlphaPlex Assay, they used a Protein A donor bead, which is a little more versatile than the anti-mouse donor beads, so they can capture a variety of species. For the AlphaPlex assay, you require a way to capture the bispecific antibody. To do so, we utilize the Fc region, however, not all bispecific antibodies have an Fc region so instead you can use the singleplex assay for any of your bispecific antibody formats.

SelectScience runs 10+ webinars a month across various scientific topics, discover more of our upcoming webinars>>


Links

Tags